ReviewReviews in endocrine & metabolic disorders2020
Acromegaly, inflammation and cardiovascular disease: a review.
Review in Reviews in endocrine & metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Pituitary adenoma and intracerebral aneurysms: case series, systematic review and meta-analysis.Pituitary · 2026Pooled it
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Soluble alpha-klotho as an adjunct biomarker of disease activity in acromegaly: Added value beyond GH and IGF-1.Pituitary · 2026Article
- Cardiovascular Implications of the Enhanced Games: Performance Enhancing Drugs in Competition and Recreation.Sports medicine - open · 2026Review
- Serum Lipidomic Profile Signature of Active Acromegaly and Relationships to Cardiovascular Disease.International journal of molecular sciences · 2026Article
- Cardiomyopathy in women with acromegaly: clinical characteristics and associated factors in a Colombian multicenter registry.Frontiers in endocrinology · 2026Article
- Diagnostic and prognostic value of myocardial work indices in evaluating cardiac function damage in active acromegaly patients.Endocrine connections · 2026Article
- Dental Implantology in Acromegaly: Pathophysiological Challenges, Biomaterial Interactions, and Future Directions-A Narrative Review.Journal of functional biomaterials · 2025Review
- Effects of Hormones on Left Heart Structure and Function with Echocardiography in Acromegaly.Reviews in cardiovascular medicine · 2025Article
- Article
- Review
- Article
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Arterial Stiffness and Subclinical Inflammation in Children with Familial Mediterranean Fever: A Comprehensive Analysis.Children (Basel, Switzerland) · 2025Article
- Joint association of systemic inflammatory response index and sarcopenia with mortality among individuals with self-reported cancer.BMC cancer · 2025Article
- The role of growth hormone in assisted reproductive technology for patients with diminished ovarian reserve: from signaling pathways to clinical applications.Frontiers in endocrinology · 2025Review
- Allostatic load index in patients with pituitary tumours: a case control study.Frontiers in endocrinology · 2025Article
- Inflamed Skin, Burdened Heart: A Multidisciplinary Perspective on Atopic Dermatitis and Cardiovascular Health.Clinical, cosmetic and investigational dermatology · 2025Review
- Acromegaly in Speckle Tracking Echocardiography-A New Cardiac Hypertrophy Phenotype? Case Report and Review.Life (Basel, Switzerland) · 2024Review
- Acromegaly: The Relationship between Hemodynamic Profiles Assessed via Impedance Cardiography and Left Ventricular Systolic Function Assessed via Echocardiography.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is characterized by Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) excess. Uncontrolled acromegaly is associated with a strongly increased risk of cardiovascular disease (CVD), and numerous cardiovascular risk factors remain present after remission. GH and IGF-1 have numerous effects on the immune and cardiovascular system. Since endothelial damage and systemic inflammation are strongly linked to the development of CVD, and have been suggested to be present in both controlled as uncontrolled acromegaly, they may explain the presence of both micro- and macrovascular dysfunction in these patients. In addition, these changes seem to be only partially reversible after remission, as illustrated by the often reported presence of endothelial dysfunction and microvascular damage in controlled acromegaly. Previous studies suggest that insulin resistance, oxidative stress, and endothelial dysfunction are involved in the development of CVD in acromegaly. Not surprisingly, these processes are associated with systemic inflammation and respond to GH/IGF-1 normalizing treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.